Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...
The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...
FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to ...
The Food and Drug Administration (FDA) has granted Fast Track designation to STM-01 for the treatment of heart failure with preserved ejection fraction ...
Johnson & Johnson (NYSE:JNJ) said on Tuesday that it received U.S. FDA's Fast Track designation for nipocalimab to treat adult patients with moderate-to-severe Sjögren's disease. In November last year ...
Pharmaceutical consultants apply their comprehensive expertise in different areas to accelerate the drug development process.
The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release ...
The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
On , US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical-an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., ...
Johnson & Johnson (NYSE:JNJ) said on Tuesday that it received U.S. FDA's Fast Track designation for nipocalimab to treat adult patients with moderate-to-severe Sjögren's disease. In November last ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback